Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Patient Blood Management in Major Orthopedic Surgery: Less Erythropoietin and More Iron?
29
Zitationen
5
Autoren
2017
Jahr
Abstract
Erythropoietin (EPO) is proposed preoperatively to reduce blood transfusion in anemic patients (hemoglobin < 13 g/dL) scheduled for a major orthopedic surgery. New intravenous iron formulations allow infusion of higher doses, increasing EPO response. In that context, we evaluated in a before-after study (n = 62 and 65 patients for each period) a new EPO administration protocol (2 injections 4 and 3 weeks before surgery, and a third if hemoglobin <13 g/dL instead of <15 g/dL 2 weeks before surgery). After this protocol implementation, the mean (standard deviation) number of EPO injections decreased from 2.8 (0.5) to 2.2 (0.4)/patient (P < .0001) without changing transfusion rates (3% in the 2 periods).
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.186 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.208 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.393 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.044 Zit.
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
1987 · 2.019 Zit.